Kelly Shimabukuro, MD
Hematology & Oncology · Honolulu, HINPI 1821166448
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 31.3% of the total.
Across 30 payments — averaging $78.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$736
- AstraZeneca$361
- Pfizer$225
- AVEO Pharmaceuticals, Inc.$161
- Ferring Pharmaceuticals Inc.$138
- Blueprint Medicines Corporation$131
- plus $600 from 8 others
What the payments were for
- Food & beverage$2,25396%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 11 | $736 |
| AstraZeneca | 3 | $361 |
| Pfizer | 2 | $225 |
| AVEO Pharmaceuticals, Inc. | 3 | $161 |
| Ferring Pharmaceuticals Inc. | 1 | $138 |
| Blueprint Medicines Corporation | 1 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Stemline Therapeutics Inc. | 1 | $112 |
| Sanofi | 1 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Pharming Healthcare, Inc. | 1 | $71 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $40 |
| Bayer | 2 | $35 |
| Viiv Healthcare Company | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$702
- XTANDI$225
- ADSTILADRIN$138
- TAGRISSO$135
- GAVRETO$131
- FOTIVDA$125
- LIVTENCITY$125
- ELZONRIS$112
- DATROWAY$102
- JEVTANA$101
How this compares
$2,352 in reported general payments places this provider in the 60th percentile of 42 hematology & oncology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 40 | $995,149 |
| IbrancePalbociclib | 43 | $666,404 |
| CabometyxCabozantinib S-Malate | 32 | $594,780 |
| FotivdaTivozanib Hcl | 14 | $449,111 |
| XtandiEnzalutamide | 34 | $414,785 |
| BrukinsaZanubrutinib | 30 | $374,491 |
| TagrissoOsimertinib Mesylate | 20 | $332,539 |
| SprycelDasatinib | 27 | $298,408 |
| Lenalidomide | 23 | $290,168 |
| JakafiRuxolitinib Phosphate | 30 | $287,066 |
| ImbruvicaIbrutinib | 13 | $230,828 |
| NinlaroIxazomib Citrate | 13 | $176,025 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $171,954 |
| TafinlarDabrafenib Mesylate | 11 | $158,392 |
| ProcritEpoetin Alfa | 15 | $63,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $736 | $1,293,55767 claims |
| PfizerIbrance, Nivestym, Eliquis | $225 | $695,55979 claims |
| AstraZenecaTagrisso | $361 | $332,53920 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $40 | $230,82813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $125 | $176,02513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 42 hematology & oncology providers in Hawaii.
Other hematology & oncology in Honolulu
- Tamie KernsHonolulu$48K
- David TamuraHonolulu$31K
- Melvin PalalayHonolulu$20K
- Ryon NakasoneHonolulu$20K
- Arnold YeeHonolulu$17K
- Jared AcobaHonolulu$15K
- Swaty AroraHonolulu$15K
- William LouiHonolulu$12K
- Jodi KagiharaHonolulu$7K
- Nicolas VillanuevaHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.